Liu Jia, Zhang Yunqi, Xu Xiaoyu, Dong Xi, Pan Yunfeng, Sun Xiaobo, Luo Yun
Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China; Diabetes Research Center, Chinese Academy of Medical Sciences, Beijing, China; Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, China; Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China; Department of Pharmacy, Shanghai YangZhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, Shanghai, 201619, China.
Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China; Diabetes Research Center, Chinese Academy of Medical Sciences, Beijing, China; Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, China.
Pharmacol Res. 2025 Jan;211:107562. doi: 10.1016/j.phrs.2024.107562. Epub 2024 Dec 26.
Diabetic retinopathy (DR) is a blinding complication of microangiopathy. First-line therapeutic drugs are all focused on late-stage DR and have several side effects, which could not meet clinical needs. The plant-derived ginsenoside Ro (Ro) has a variety of effective anti-inflammatory, immune-regulating, and cardiovascular protective effects, but its microvascular protective effects are rarely studied. This study aimed to explore the protective effect and mechanism of Ro on retinal microvascular endothelial cells in early stage of DR. We demonstrated that Ro exerted endothelial cell protection by regulating mitochondrial oxidative stress and autophagy in AGEs-injured endothelial cells. Moreover, Ro alleviated DR progress through improving retinal thickness and pathological changes in STZ-induced diabetic mice. Mechanically, Ro promotes the activation of Epac1-mediated AMPK signaling. On the contrary, the protective effects of Ro were abolished by Epac1 inhibitor in vitro or Epac1 knock down in vivo. Our results revealed the important role of Ro on the treatment of DR and suggested that targeting Epac1 may be a promising approach to prevent and treat DR.
糖尿病视网膜病变(DR)是微血管病变导致的致盲并发症。一线治疗药物均聚焦于晚期DR,且有多种副作用,无法满足临床需求。植物源人参皂苷Ro(Ro)具有多种有效的抗炎、免疫调节和心血管保护作用,但其微血管保护作用鲜有研究。本研究旨在探讨Ro对DR早期视网膜微血管内皮细胞的保护作用及机制。我们证明Ro通过调节线粒体氧化应激和自噬对晚期糖基化终末产物(AGEs)损伤的内皮细胞发挥内皮细胞保护作用。此外,Ro通过改善链脲佐菌素(STZ)诱导的糖尿病小鼠的视网膜厚度和病理变化减轻DR进展。机制上,Ro促进Epac1介导的AMPK信号通路的激活。相反,Epac1抑制剂在体外或体内敲低Epac1可消除Ro的保护作用。我们的结果揭示了Ro在DR治疗中的重要作用,并表明靶向Epac1可能是预防和治疗DR的一种有前景的方法。